Recruiting Pulmonary Hypertension Studies in Calgary
NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)
This is a Phase 2, open-label, multi-center, 2-part study of NS-089/NCNP-02 administered by weekly IV infusion to ambulant boys aged ≥4 to \<15 years with DMD due to mutations amenable to exon 44 skip...
NS-050/NCNP-03 in Boys With DMD (Meteor50)
This is a Phase 1/2 study of Multiple-Ascending Dose (MAD) levels for 12 weeks of treatment followed by 24 weeks of open-label treatment with a selected dose of NS-050/NCNP-03 administered once weekly...
About Pulmonary Hypertension Clinical Trials in Calgary
Pulmonary hypertension is a type of high blood pressure that affects the arteries in the lungs and the right side of the heart. It can lead to heart failure if untreated. Treatment includes vasodilators, endothelin receptor antagonists, and PDE-5 inhibitors.
There are currently 2 pulmonary hypertension clinical trials recruiting participants in Calgary, ALBERTA. These studies are seeking a combined 40 participants. Research is being sponsored by NS Pharma, Inc.. Clinical trial participation is free and participants receive study-related medical care at no cost.
Pulmonary Hypertension Clinical Trials in Calgary — FAQ
Are there pulmonary hypertension clinical trials in Calgary?
Yes, there are 2 pulmonary hypertension clinical trials currently recruiting in Calgary, ALBERTA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Calgary?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Calgary research site will contact you about next steps.
Are clinical trials in Calgary free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Calgary studies also compensate for your time and travel.
What pulmonary hypertension treatments are being tested?
The 2 active trials in Calgary are testing new therapies including novel drugs, biologics, and treatment approaches for pulmonary hypertension.
Data updated March 2, 2026 from ClinicalTrials.gov